What's Happening?
Inhibrx Biosciences is set to host a webcast presentation to provide a clinical update on its Phase 1/2 study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer. The webcast will
take place on April 21, 2026, at 1:30 p.m. PT. Ozekibart is a DR5 agonist antibody designed to induce tumor-biased cell death. The FDA has granted Fast Track and orphan drug designations to ozekibart for chondrosarcoma. Inhibrx is also investigating ozekibart in other tumor types, including Ewing sarcoma.
Why It's Important?
The clinical update on ozekibart represents a significant step in the development of new treatments for colorectal cancer, a condition with limited therapeutic options. The webcast will provide insights into the progress of Inhibrx's trials and the potential of ozekibart as a treatment for various cancers. The FDA's designations highlight the drug's promise and the need for innovative therapies in oncology. Successful development of ozekibart could lead to new treatment paradigms and improve outcomes for patients with difficult-to-treat cancers.
What's Next?
Following the webcast, Inhibrx will update its corporate presentation and continue its clinical trials for ozekibart. The company will focus on advancing its pipeline and exploring additional therapeutic candidates. The outcomes of the ongoing trials will be crucial in determining the future of ozekibart and its potential approval for clinical use. Inhibrx's efforts will be closely monitored by investors and stakeholders in the biopharmaceutical industry.
